NCT03726333: Hepatic Impairment Study for Lorlatinib in Cancer Patients

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have a biliary obstruction with a biliary drain or stent
Exclusions: Patients with unstable brain metastases; Patients with prior treatment with lorlatinib

Comments are closed.

Up ↑